SAN FRANCISCO, May 10, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced that Matthew R. Patterson,
President and Chief Executive Officer, will present at the
following upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference
Gene Therapy & Editing Panel
May 17, 2017, 1:40 PM PT
Encore at Wynn Las Vegas, Las Vegas,
NV
- UBS Global Healthcare Conference
Corporate Presentation
May 22, 2017, 11:00 AM ET
Grand Hyatt, New York, NY
To access a live webcast of the corporate presentation at the
UBS Global Healthcare Conference, please visit the Events &
Presentations page within the Investors & News section of the
Audentes website. A replay of the live webcast will remain
available on the Audentes website for approximately 30 days
following the conference. A webcast will not be available for
the Gene Therapy and Editing Panel at the Bank of America Merrill
Lynch 2017 Health Care Conference.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing gene therapy products for patients
living with serious, life-threatening rare diseases. We have
four product candidates in development, AT132 for the treatment of
X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of
Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-upcoming-investor-conferences-300454626.html
SOURCE Audentes Therapeutics, Inc.